Get started
VALNEVA SE EUR0.15VALNEVA SE EUR0.15VALNEVA SE EUR0.15

VALNEVA SE EUR0.15

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

0OB3 chart


Full chart

0OB3 upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪430.60 M‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.234 EUR
Net income (FY)
‪−101.43 M‬ EUR
Revenue (FY)
‪153.71 M‬ EUR
Shares float
‪135.73 M‬
Beta (1Y)
0.72

Employees


Employees (FY)
676
Revenue / Employee (1Y)
‪250.98 K‬ EUR
Net income / Employee (1Y)
‪−165.61 K‬ EUR

About VALNEVA SE


Sector
Health Technology
Industry
Biotechnology
CEO
Thomas Lingelbach
Website
valneva.com
Headquarters
Saint-Herblain
Founded
1999
ISIN
FR0004056851
FIGI
BBG00NRVXRS5
Valneva SE is a specialty vaccine company, which focuses on the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases. It operates through the following segments: Commercialized Products, COVID, Vaccine Candidates, and Technologies and Services. The Commercialized Products segment markets vaccines, currently IXIARO and DUKORAL vaccines, as well as third-party products. The COVID segment develops, manufactures, and distribute related to COVID-19 vaccine candidate, VLA2001. The Vaccine Candidates segment focuses on proprietary research and development programs aiming to generate new approvable products to generate future cash flows from product sales or from commercialization through partnering with pharmaceutical companies. The Technologies and Services segment offers services and inventions at a commercialization stage. The company was founded on April 7, 1999 and is headquartered in Saint-Herblain, France.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

0OB3 news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 0OB3 is 2.682 EUR — it has increased by 0.45% in the past 24 hours. Watch VALNEVA SE EUR0.15 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange VALNEVA SE EUR0.15 stocks are traded under the ticker 0OB3.
0OB3 stock has fallen by −1.70% compared to the previous week, the month change is a 2.15% rise, over the last year VALNEVA SE EUR0.15 has showed a −54.85% decrease.
We've gathered analysts' opinions on VALNEVA SE EUR0.15 future price: according to them, 0OB3 price has a max estimate of 11.00 EUR and a min estimate of 3.70 EUR. Watch 0OB3 chart and read a more detailed VALNEVA SE EUR0.15 stock forecast: see what analysts think of VALNEVA SE EUR0.15 and suggest that you do with its stocks.
0OB3 reached its all-time high on Nov 30, 2021 with the price of 29.540 EUR, and its all-time low was 2.110 EUR and was reached on Mar 17, 2020. View more price dynamics on 0OB3 chart.
See other stocks reaching their highest and lowest prices.
0OB3 stock is 2.44% volatile and has beta coefficient of 0.72. Track VALNEVA SE EUR0.15 stock price on the chart and check out the list of the most volatile stocks — is VALNEVA SE EUR0.15 there?
Today VALNEVA SE EUR0.15 has the market capitalization of ‪428.33 M‬, it has decreased by −0.82% over the last week.
Yes, you can track VALNEVA SE EUR0.15 financials in yearly and quarterly reports right on TradingView.
VALNEVA SE EUR0.15 is going to release the next earnings report on Nov 7, 2024. Keep track of upcoming events with our Earnings Calendar.
0OB3 earnings for the last quarter are −0.17 EUR per share, whereas the estimation was −0.16 EUR resulting in a −11.26% surprise. The estimated earnings for the next quarter are −0.12 EUR per share. See more details about VALNEVA SE EUR0.15 earnings.
VALNEVA SE EUR0.15 revenue for the last quarter amounts to ‪38.08 M‬ EUR, despite the estimated figure of ‪41.34 M‬ EUR. In the next quarter, revenue is expected to reach ‪44.95 M‬ EUR.
0OB3 net income for the last quarter is ‪−24.93 M‬ EUR, while the quarter before that showed ‪58.91 M‬ EUR of net income which accounts for −142.32% change. Track more VALNEVA SE EUR0.15 financial stats to get the full picture.
No, 0OB3 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 5, 2024, the company has 676.00 employees. See our rating of the largest employees — is VALNEVA SE EUR0.15 on this list?
Like other stocks, 0OB3 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade VALNEVA SE EUR0.15 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So VALNEVA SE EUR0.15 technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating VALNEVA SE EUR0.15 stock shows the sell signal. See more of VALNEVA SE EUR0.15 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.